Interestingly, wtTRPM7 (M7-wt) increase the CD133 and ALDH1 expression in all glioma cell lines tested, however dead kinase domain of TRPM7 (M7-KR and M7-DK) downregulate the expression of CD133 and ALDH1 compared to controls (M7-wt), which indicates that disruption of kinase domain would reduce the TRPM7 activation resulting in reduced activation of stem cell markers CD133 and ALDH1. Here, ALDH1A1 is linked to central nervous system cancer.